Tandem backs use of insulin pump
By HME News Staff
Updated 10:13 AM CST, Tue November 15, 2022
SAN DIEGO – Tandem Diabetes Care has announced the results from a prospective, multi-center, single-arm study of adults living with Type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology. Data from the study, which was presented at the 22nd Annual Diabetes Technology Meeting, demonstrated the system to be safe during six weeks of use, with a substantial improvement in time in range and mean glucose related to a reduction in hyperglycemia and no increase in continuous glucose monitor-measured hypoglycemia. Both prior multiple daily injection users and prior basal insulin only users showed similar levels of improvement. “Our goal with this study was to show Control-IQ technology was safe and could offer considerable benefit to individuals with Type 2 diabetes, and we accomplished that,” said Carol Levy, MD, CDCES, protocol chair for the study and professor of medicine, Division of Endocrinology, Diabetes and Bone Disease, at the Icahn School of Medicine at Mount Sinai. “The 15% time in range improvement from prior therapy represents a 3.6 hour/day increase in time in range, with no hypoglycemia events.” The study included 30 adults with Type 2 diabetes from three clinical centers: Icahn School of Medicine at Mount Sinai, New York City, NY; Mayo Clinic, Rochester, Minn.; and Texas Diabetes and Endocrinology, Austin, Texas. The study was coordinated by the JAEB Center for Health Research, in Tampa, Fla.
Comments